ReShape Lifesciences Inc.

NasdaqCM:RSLS Stock Report

Market Cap: US$3.2m

ReShape Lifesciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:RSLS Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
31 May 24SellUS$39Thomas StankovichIndividual2.97US$14.50

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of RSLS?
Owner TypeNumber of SharesOwnership Percentage
Institutions4,3060.604%
Individual Insiders37,4295.25%
General Public670,94594.1%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 123.2%.

Top Shareholders

Top 15 shareholders own 5.87% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
5.25%
Yair Schneid
37,407US$169.1k-11.8%no data
0.32%
Geode Capital Management, LLC
2,285US$10.3k0%no data
0.12%
The Vanguard Group, Inc.
859US$3.9k0%no data
0.093%
Tower Research Capital Europe Limited
665US$3.0k321%no data
0.083%
BlackRock, Inc.
588US$2.7k0.17%no data
0.0021%
Dan Gladney
15US$67.67.14%no data
0.00098%
Thomas Stankovich
7US$31.6-98.2%no data
0.00056%
Bank of America Corporation, Asset Management Arm
4US$18.033.3%no data
0.00042%
Cornerstone Planning Group Inc.
3US$13.550%no data
0.00028%
Group One Trading LP, Asset Management Arm
2US$9.0100%no data
0.00014%
CIBC Private Wealth Advisors, Inc.
1US$4.50%no data
0.00014%
UBS Asset Management AG
1US$4.5-99.9%no data
0.00014%
Morgan Stanley, Investment Banking and Brokerage Investments
1US$4.50%no data
0.00014%
JPMorgan Chase & Co, Brokerage and Securities Investments
1US$4.50%no data
0.00014%
Planned Solutions Financial & Insurance Services, Inc.
1US$4.50%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/31 04:28
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ReShape Lifesciences Inc. is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
William PlovanicCanaccord Genuity
Matthew HewittCraig-Hallum Capital Group LLC
Jeffrey CohenLadenburg Thalmann & Company